Skip to content
Sign in
Health · North America

HHS permits compounding of six unapproved peptides despite FDA scientists’ safety concerns

HHS has adopted a temporary enforcement policy allowing compounding pharmacies to make six unapproved peptides while the agency revises formal regulations. STAT says FDA career scientists objected, citing limited evidence about the peptides’ safety or effectiveness.

AI-assisted synthesis · Based on 4 outlets' reporting · Article text read from 1 of 4 outlets · short excerpt from 1 moreHow it's made

View timeline · 6 entries
4 outletsLatest reporting 3 min readNo new reporting in 4 days
Coverage: Too few ratedL 0 · C 2 · R 0 · 2 unrated
Updat3 graphic: North America
Updat3 graphic · Map data: Natural Earth Natural Earth (public domain)

What happened

Key facts

  • HHS adopted a temporary policy allowing pharmacies to compound six peptides that are not FDA-approved (per ssbcrack.com, STAT, medicaldaily.com).
  • The six peptides are BPC-157, epitalon, KPV, MOTS-c, semax and TB-500 (per ssbcrack.com).
  • HHS describes the temporary policy as enforcement discretion, meaning it will refrain from legal action against pharmacies for producing the peptides (per ssbcrack.com).
  • FDA career scientists objected to the policy, citing scant evidence that the peptides are safe or effective (per STAT).
  • HHS says the policy does not mean the peptides are safe or FDA-approved (per medicaldaily.com, ssbcrack.com, STAT).
  • Health Secretary Robert F. Kennedy Jr. has said he is a “big fan” of peptides (per ssbcrack.com).

The brief

HHS has temporarily allowed compounding pharmacies to make six peptides that have not been approved by the FDA, while the department continues revising formal regulations. STAT reported that FDA career scientists objected, pointing to scant evidence that the substances are safe or effective.

The peptides covered by the policy are BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. HHS is using what it calls “enforcement discretion”: according to SSBCRack, the agency will refrain from taking legal action against pharmacies that produce these unapproved substances during the temporary policy.

Medical Daily’s headline says the authorization applies to licensed pharmacies and stresses that HHS says the policy does not make the peptides safe or FDA-approved. STAT’s headline also describes the policy as covering licensed pharmacies and physicians, while SSBCRack’s account refers to compounding pharmacies.

The reported policy concerns permission to compound the named substances, not FDA approval of them. The decision arrives as HHS works on revisions to formal regulations governing the substances. SSBCRack reports that Health Secretary Robert F. Kennedy Jr. has called himself a “big fan” of peptides.

The available account does not connect that statement to the agency’s policy decision. SSBCRack also describes a market in which retailers sell similar peptides under a “for research use only” label. It says the label is used to avoid rules barring sales for human consumption.

That account presents the market as context for the policy, but does not establish that the temporary compounding authorization covers those retail sales.

Shabbir Safdar, director of the Partnership for Safe Medicines, warned that relaxed enforcement and the pending rule change could expose people to “untested dangerous substances.” His warning identifies a potential public-health risk; STAT separately reports that FDA career scientists raised concerns about the limited safety and effectiveness evidence.

The central regulatory distinction is between temporary enforcement discretion and FDA approval: HHS is allowing compounding for the six named peptides while formal rules remain under revision, but the policy itself does not establish that the substances are safe or approved. The sources describe no final regulatory decision beyond that ongoing revision process.

Why it matters

  • Compounding pharmacies may produce six unapproved peptides under HHS’s temporary enforcement discretion, even as FDA career scientists cited limited evidence of safety and effectiveness.
  • People exposed to the peptides could face the risk identified by Shabbir Safdar: contact with substances he described as untested and dangerous.
  • The distinction matters for patients and pharmacies: HHS’s temporary policy permits compounding, while Medical Daily’s headline says it does not confer FDA approval or establish safety.

What to watch next

  • Whether HHS continues revising formal regulations for the six peptides.
  • Whether FDA career scientists’ safety and effectiveness concerns are addressed in the formal regulatory revisions.
  • Whether HHS maintains its stated enforcement discretion for pharmacies compounding the six peptides.

How it's being covered

Coverage analysisShow details
4 source articles · 4 unique outlets
Outlet political mix: Too few rated· 2 Center · 2 unrated
Where the outlets are based: Unknown 75% · Global 25%
Outlet political mix
Too few rated
Left
Center
Right
0 outlets
2 outlets
0 outlets
The marker shows coverage balance: each unique outlet counts once. 2 unrated outlets are not included.
Geography
Where the outlets covering this story are based.
4 unique outletsDominant coverage: Global
Coverage imbalance
  • Coverage is currently concentrated among outlets based in Unknown (3 of 4 geographically-identified sources).
How we measure coverage

How outlets' accounts compare

Updat3 does not yet have enough full reports to compare how outlets framed this story.

Timeline

Developments from this story's sources, dated background we compiled and fact-checked, and our earlier coverage. Each row says which.
  1. President Franklin D. Roosevelt signed the Federal Food, Drug, and Cosmetic Act, expanding federal oversight of food, drugs and cosmetics.
    Background · compiled and fact-checked by Updat3
  2. President John F. Kennedy signed the Kefauver-Harris Amendments, requiring evidence of drug effectiveness as well as safety.
    Background · compiled and fact-checked by Updat3
  3. President Bill Clinton signed the FDA Modernization Act, adding Section 503A to the Federal Food, Drug, and Cosmetic Act.
    Background · compiled and fact-checked by Updat3
  4. President Barack Obama signed the Drug Quality and Security Act, setting rules for bulk substances used in section 503A compounding.
    Background · compiled and fact-checked by Updat3
  5. The FDA placed six peptide bulk drug substances in a category for substances raising significant safety concerns.
    Background · compiled and fact-checked by Updat3
  6. The Senate confirmed Robert F. Kennedy Jr. as secretary of Health and Human Services.
    Background · compiled and fact-checked by Updat3

How we got here

In 2023, the FDA placed several bulk substances nominated for pharmacy compounding—including BPC-157 and other peptides—on its Category 2 list, which identifies substances the agency believes may present significant safety risks.

The legal framework dates to the Food and Drug Administration Modernization Act of 1997, which added Section 503A to the Federal Food, Drug, and Cosmetic Act.

Original sources

3 of 4 articles · Unknown · Show all

Every story links to the reporting it was built from. How we choose sources

Spotted a factual error, a broken link or a misleading summary? Tell us.